Three pillars. Three execution pathways.
Parallel development with indication-specific collaborators, on one shared engineering and CMC backbone.
Where each program stands today.
| Program | Pillar | Design | Stage |
|---|---|---|---|
| Radiation injury · UHRP-Bridge | Off-the-shelf | Permanent invisibility · Temporary graft | Preclinical · Lead |
| SCD & β-thalassemia | Off-the-shelf | Permanent invisibility · Durable graft | Preclinical |
| SCID & selected IEIs | Off-the-shelf | Developmental invisibility · Durable graft | Preclinical |
| Transplant tolerance | Autologous | Molecular mixed chimerism | Platform direction |
| Autoimmune disease | Autologous | Lineage-directed immunoregulation | Exploratory |
| ECEP | Bedside engineering | Closed, automated point-of-care manufacturing | Enabling tech · In development |
All three off-the-shelf indications are preclinical. ECEP is an enabling manufacturing technology for future use and is not required for the lead program's first IND-enabling path.
An 18–24 month plan to the next value inflection.
Moving from platform architecture to disease-relevant in vivo validation and one prioritized IND-enabling path.
Grant applications supporting the platform.
Hemavive is pursuing federal, state and foundation funding alongside private capital. Status below is current as of this page; no application listed here has been awarded.
| Application | Supports | Status |
|---|---|---|
| SBIR | Radiation injury · UHRP-Bridge | Submitted · Under review |
| TEDCO Equitech Growth Fund | ECEP · bedside engineering | Submitted · Under review |
| Breakthrough T1D | HSPC immune-engineering platform | Reviewed · Under further assessment |
| SBIR | Hemoglobinopathies · SCID & selected IEIs | Submission planned · January |
| NIH R61 / R33 | Selected programs across the platform | In preparation |
Three programs. Three markets. Multiple paths to revenue.
A diversified model across government preparedness, rare-disease transplantation, and global hemoglobinopathy access.
The radiation opportunity is a government preparedness market, not a patient-count TAM. The hemoglobinopathy opportunity reflects prevalence and long-term access, not a near-term treated-patient count. Sources: Sidra Medicine, BARDA / ASPR, SCID newborn-screening literature, WHO / CDC / TIF.
Off-the-shelf access, without one fixed immune state for every disease.
Hemavive does not recreate an HSC — it engineers the clinically proven one, and tunes immune visibility to the biology of each indication.
Low rejection risk, but available only after single-patient manufacturing — one slow lot per patient.
Depends on finding a matched donor; conventional manufacturing, with GVHD and rejection risk.
Off-the-shelf and scalable, but one fixed immune profile applied to every use case.
Off-the-shelf and banked, with immune visibility tuned per disease: permanent, temporary, or developmental.
Investor and partner materials.
Hemavive is engaging with strategic investors, grant partners, engineering partners and scientific collaborators. Financing detail is shared directly.